An electric field can be applied to a microfluidic device in order to stop particle flow. Electroosmosis, electrophoresis, and dielectrophoresis act on the particles in different directions in the microfluidic channel, and when these forces create zero net force, the particle stops in the channel. The goal of the performed experiments is to investigate whether hydrostatic pressure generated by a syringe pump could help concentrate these particles and separate them from other contents. Introducing precise, adjustable hydrostatic pressure from the syringe pump provides another mechanism for controlling particle behavior. A microfluidic channel was crafted into a device connected to a syringe pump, and videos of 1 µm silica particles in the device were recorded under a microscope in order to show that samples could be infused into the device and concentrated or captured at a specific location in the channel using hydrostatic pressure. Capture of the particles occurred with and without controlled hydrostatic pressure, but these events occurred somewhat consistently at different voltages. In addition, particle movement in the channel with the syringe pump off was originally attributed to the electrokinetic forces. However, when compared to experiments without the syringe pump connected to the device, it became evident that the electrokinetic forces should have moved the particles in the opposite direction and that, in actuality, there is an inherent pressure in the device also affecting particle movement even when the syringe pump is not turned on.

Virus-like particles (VLPs) are optimum candidates for creating vaccines, as they are highly flexible, adaptable, safe, and similar to the structural proteins of the target cells. The COVID 19 pandemic has increased the need to create effective and safe vaccines that can be mass produced to stop the spread of COVID-19. Till now, various types of vaccine platforms have been utilized to create COVID-19 vaccines, each with unique characteristics and techniques. It is essential to use robust vaccine platforms that can deliver optimum results in a short period of time, with minimal risks. The structural proteins found in SARS-CoV-2, such as Spike (S) protein have been widely targeted to induce antibody response, also called a humoral response, which is a part of acquired immunity. The other structural proteins such as M (membrane) and E (envelope) can also be used as targets for antibodies. The S2 and glycoprotein (S full) can be used to induce an efficient IgG response. Therefore, the incorporation of structural proteins into VLPs can prove to be useful. Furthermore, double mosaic VLPs employs double epitopes, which can effectively cover the distances between the S proteins, thus optimizing the B cell activation process. This review describes the various developments that have taken place in the field of VLPs and more specifically, with regards to developing VLP vaccines against the SARS-CoV-2 virus.